Literature DB >> 30261153

The significance of SUMOylation of angiogenic factors in cancer progression.

Mei Wang1, Xiaodong Jiang2.   

Abstract

Angiogenesis is the process of endothelial cell migration and proliferation induced by angiogenic factors, which is essential for the development of tumors. In recent years, studies have reported that SUMOylation acts on tumor angiogenesis by targeting angiogenic factors as one of post-translational modifications of proteins. Anti-angiogenic therapy is a new treatment method for tumor treatment following radiotherapy and chemotherapy, and it inhibits tumor growth by blocking tumor blood vessels. Therefore, SUMOylation may become a potential target for anti-angiogenesis therapy. This article focuses on the effect of SUMOylation on vascular growth factors, important signaling pathways proteins, and the migration and function of endothelial cells, in order to provide a new research idea for the anti-angiogenic therapy of tumors.

Entities:  

Keywords:  SUMOylation; angiogenic factors; cancer

Year:  2018        PMID: 30261153      PMCID: PMC6343704          DOI: 10.1080/15384047.2018.1523854

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  60 in total

Review 1.  "IF-pathies": a broad spectrum of intermediate filament-associated diseases.

Authors:  M Bishr Omary
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

2.  Sumoylation differentially regulates Sp1 to control cell differentiation.

Authors:  Lili Gong; Wei-Ke Ji; Xiao-Hui Hu; Wen-Feng Hu; Xiang-Cheng Tang; Zhao-Xia Huang; Ling Li; Mugen Liu; Shi-Hua Xiang; Erxi Wu; Zachary Woodward; Yi-Zhi Liu; Quan Dong Nguyen; David Wan-Cheng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-27       Impact factor: 11.205

Review 3.  SUMO-specific proteases and isopeptidases of the SENP family at a glance.

Authors:  Kathrin Kunz; Tanja Piller; Stefan Müller
Journal:  J Cell Sci       Date:  2018-03-20       Impact factor: 5.285

4.  Pias1 is essential for erythroid and vascular development in the mouse embryo.

Authors:  Jerfiz D Constanzo; Mi Deng; Smita Rindhe; Ke-Jing Tang; Cheng-Cheng Zhang; Pier Paolo Scaglioni
Journal:  Dev Biol       Date:  2016-05-04       Impact factor: 3.582

5.  Nuclear localisation of endogenous SUMO-1-modified PDGF-C in human thyroid tissue and cell lines.

Authors:  Laila J Reigstad; Aurora Martinez; Jan Erik Varhaug; Johan R Lillehaug
Journal:  Exp Cell Res       Date:  2006-01-26       Impact factor: 3.905

6.  Negative Regulation of AKT Activation by BRCA1.

Authors:  Tao Xiang; Amiko Ohashi; Yuping Huang; Tej K Pandita; Thomas Ludwig; Simon N Powell; Qin Yang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate.

Authors:  Isao Fukuda; Akihiro Ito; Go Hirai; Shinichi Nishimura; Hisashi Kawasaki; Hisato Saitoh; Ken-Ichi Kimura; Mikiko Sodeoka; Minoru Yoshida
Journal:  Chem Biol       Date:  2009-02-27

8.  SUMOylation Negatively Regulates Angiogenesis by Targeting Endothelial NOTCH Signaling.

Authors:  Xiaolong Zhu; Sha Ding; Cong Qiu; Yanna Shi; Lin Song; Yueyue Wang; Yuewen Wang; Jinying Li; Yiran Wang; Yi Sun; Lingfeng Qin; Jun Chen; Michael Simons; Wang Min; Luyang Yu
Journal:  Circ Res       Date:  2017-07-31       Impact factor: 17.367

9.  Inhibition of PDGF-B induction and cell growth by syndecan-1 involves the ubiquitin and SUMO-1 ligase, Topors.

Authors:  Kathleen R Braun; Allison M DeWispelaere; Steven L Bressler; Nozomi Fukai; Richard D Kenagy; Lihua Chen; Alexander W Clowes; Michael G Kinsella
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.

Authors:  James R Brown; Kristen L Conn; Peter Wasson; Matthew Charman; Lily Tong; Kyle Grant; Steven McFarlane; Chris Boutell
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.